Printer Friendly

ABBOTT LABORATORIES TRANSFERS HIVIG TO NORTH AMERICAN BIOLOGICALS, INC.

ABBOTT LABORATORIES TRANSFERS HIVIG TO NORTH AMERICAN BIOLOGICALS, INC.
 ABBOTT PARK, Ill., and MIAMI, Nov. 4 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) and North American Biologicals, Inc. (NABI) today announced the complete transfer from Abbott to NABI of HIV Immune Globulin (HIVIG), an experimental immune globulin which may prevent the transmission of AIDS from HIV-positive mothers to unborn infants.
 Effective immediately, Abbott is transferring to NABI the rights and assets associated with HIVIG, including commercial rights, existing inventory, Phase I clinical safety data, Orphan Drug status, patent portfolio, equipment, raw material, and manufacturing technology and specifications. NABI will now have responsibility for the development, manufacture and commercialization of HIVIG.
 "We are very pleased that this will expedite the availability of HIVIG for clinical studies," said Dr. David Milligan, vice president, diagnostic products research and development for Abbott. "Through continuous efforts we have agreed to transfer all HIVIG assets and have worked out a process which allows NABI to develop and manufacture HIVIG independently. As one of the world's largest providers of human blood plasma elements, NABI has both the access to high quality human plasma and the expertise in testing plasma necessary to develop and commercialize HIVIG," he added.
 "We are extremely pleased at the opportunity to develop a new weapon in the fight against pediatric AIDS," said David J. Gury, NABI's chairman, president and chief executive officer. "The National Institutes of Health has planned comprehensive clinical trials of HIV immune globulin to determine its efficacy as a means of providing passive immunity to infants of HIV-positive mothers. NABI will immediately seek to participate in these trials," Gury added.
 NABI obtained from Abbott the exclusive right to acquire HIVIG in October 1992, as part of NABI's acquisition of Abbott's H-BIG product, a plasma-based product for Hepatitis B.
 HIVIG is prepared from the plasma of HIV antibody positive donors who are healthy and have a strong immune response to the virus. The product is derived from plasma which is processed to collect high concentrations of antibodies to HIV.
 Abbott Laboratories is a worldwide manufacturer of health care products employing 47,000 people. In 1991, the company's sales and net earnings were $6.9 billion and $1.1 billion, respectively, with earnings per share of $2.55.
 North American Biologicals, Inc., headquartered in Miami, is the world's largest independent provider of human blood plasma elements to the health care industry.
 -0- 11/4/92
 /CONTACT: Traci Lance of Abbott Labs, 708-938-3895, David J. Gury or Al Fernandez of NABI, 305-625-5303; or Marcia A. Kean of Feinstein Partners, 617-577-8110, for Abbott Laboratories/
 (ABT) CO: Abbott Laboratories; North American Biologicals, Inc. ST: Illinois, Florida IN: MTC SU:


AH -- NY056 -- 2560 11/04/92 14:04 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 4, 1992
Words:451
Previous Article:NISSAN POSTS 15.5 PERCENT SALES INCREASE, FUELED BY NEW ALTIMA
Next Article:WHEELING-PITTSBURGH STEEL CORPORATION ELECTS VICE PRESIDENT-OPERATIONS
Topics:


Related Articles
NORTH AMERICAN BIOLOGICALS REPORTS YEAR-END 1991 RESULTS
NABI SEEKS TO MARKET THIRD VIROCHEQC DIAGNOSTIC PRODUCT; VIROCHEQC I SERVES AS MULTI-CONSTITUENT CONTROL FOR HIV 1&2 AND HEPATITIS MARKERS
NORTH AMERICAN BIOLOGICALS, INC. REPORTS SECOND QUARTER 1992 RESULTS; SALES AND OPERATING INCOME AT RECORD LEVELS FOR QUARTER AND YEAR TO DATE
NORTH AMERICAN BIOLOGICALS, INC. ANNOUNCES THIRD QUARTER AND YEAR-END 1992 OUTLOOK
NORTH AMERICAN BIOLOGICALS, INC. CREATES HIVIG PRODUCTION FACILITY; PILOT LAB CONSTRUCTED; COLLECTION CENTER SEEKS SPECIAL LICENSE
NORTH AMERICAN BIOLOGICALS, INC. ALLOWED EUROPEAN PATENT FOR HIVIG: PRODUCT MAY PREVENT HIV TRANSMISSION TO INFANTS
NABI ESTABLISHES SCIENTIFIC ADVISORY BOARD WITH IMMUNOLOGISTS, VIROLOGISTS AND PEDIATRICIANS FROM LEADING MEDICAL INSTITUTIONS
NORTH AMERICAN BIOLOGICALS COMPLETES ACQUISITION OF MAJOR PLASMA COMPANY
Abbott and North American Vaccine Form Marketing Alliance
North American Vaccine Advised by FDA That CERTIVA(TM) Licensure Review Is Nearly Complete

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters